Condition
RDEB
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Active Not Recruiting1
Recruiting1
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07193134Phase 1RecruitingPrimary
GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment
NCT05725018Phase 3Active Not Recruiting
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
NCT05708677Enrolling By InvitationPrimary
A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB
Showing all 3 trials